Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

计划入组 16 人 · 首次发布于 2024 年 12 月 13 日

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

计划入组 8 人 · 首次发布于 2025 年 2 月 19 日

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

计划入组 18 人 · 首次发布于 2025 年 6 月 9 日

COL7A1 gene editing therapy (Trucode Gene)

Recombinant human type VII collagen

Coagulation factor VII human(Balfaxar, Beriplex, Kcentra, Octaplex)

JIUYUAN GENE

King Edward VII Memorial Hospital

Bermuda

Triple-Gene LLC

United States

Stanford Medicine Gene Therapy Skin Grafts Show 81% Healing Rate in Phase 3 Epidermolysis Bullosa Trial

DEBRA Research and Nonsense Therapeutics Form ReadOn Therapeutics to Advance Epidermolysis Bullosa Treatments

FDA Accepts Abeona Therapeutics' BLA Resubmission for Pz-cel in Recessive Dystrophic Epidermolysis Bullosa